Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome

Saurabh K. Garg, Daniel T. Lioy, Hélène Cheval, James C. McGann, John M. Bissonnette, Matthew J. Murtha, Kevin D. Foust, Brian K. Kaspar, Adrian Bird, Gail Mandel

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

De novo mutations in the X-linked gene encoding the transcription factor methyl-CPG binding protein 2 (MECP2) are the most frequent cause of the neurological disorder RETT syndrome (RTT). Hemizygous males usually die of neonatal encephalopathy. Heterozygous females survive into adulthood but exhibit severe symptoms including microcephaly, loss of purposeful hand motions and speech, and motor abnormalities, which appear after a period of apparently normal development. Most studies have focus edon male mouse models because of the shorter latency to and severity in symptoms, yet how well these mice mimic the disease in affected females is not clear. Very few therapeutic treatments have been proposed for females, the more gender-appropriate model. Here, we show that self-complementary AAV9, bearing MeCP2 CDNA under control of a fragment of its own promoter (scAAV9/MeCP2), is capable of significantly stabilizing or reversing symptoms when administered systemically into female RTT mice. To our knowledge, this is the first potential gene therapy for females afflicted with RTT.

Original languageEnglish (US)
Pages (from-to)13612-13620
Number of pages9
JournalJournal of Neuroscience
Volume33
Issue number34
DOIs
StatePublished - 2013

Fingerprint

Rett Syndrome
Microcephaly
X-Linked Genes
Brain Diseases
Nervous System Diseases
Genetic Therapy
Carrier Proteins
Transcription Factors
Hand
Mutation
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. / Garg, Saurabh K.; Lioy, Daniel T.; Cheval, Hélène; McGann, James C.; Bissonnette, John M.; Murtha, Matthew J.; Foust, Kevin D.; Kaspar, Brian K.; Bird, Adrian; Mandel, Gail.

In: Journal of Neuroscience, Vol. 33, No. 34, 2013, p. 13612-13620.

Research output: Contribution to journalArticle

Garg, SK, Lioy, DT, Cheval, H, McGann, JC, Bissonnette, JM, Murtha, MJ, Foust, KD, Kaspar, BK, Bird, A & Mandel, G 2013, 'Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome', Journal of Neuroscience, vol. 33, no. 34, pp. 13612-13620. https://doi.org/10.1523/JNEUROSCI.1854-13.2013
Garg, Saurabh K. ; Lioy, Daniel T. ; Cheval, Hélène ; McGann, James C. ; Bissonnette, John M. ; Murtha, Matthew J. ; Foust, Kevin D. ; Kaspar, Brian K. ; Bird, Adrian ; Mandel, Gail. / Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome. In: Journal of Neuroscience. 2013 ; Vol. 33, No. 34. pp. 13612-13620.
@article{f84bfebf43564a3abd3ac4f663587355,
title = "Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome",
abstract = "De novo mutations in the X-linked gene encoding the transcription factor methyl-CPG binding protein 2 (MECP2) are the most frequent cause of the neurological disorder RETT syndrome (RTT). Hemizygous males usually die of neonatal encephalopathy. Heterozygous females survive into adulthood but exhibit severe symptoms including microcephaly, loss of purposeful hand motions and speech, and motor abnormalities, which appear after a period of apparently normal development. Most studies have focus edon male mouse models because of the shorter latency to and severity in symptoms, yet how well these mice mimic the disease in affected females is not clear. Very few therapeutic treatments have been proposed for females, the more gender-appropriate model. Here, we show that self-complementary AAV9, bearing MeCP2 CDNA under control of a fragment of its own promoter (scAAV9/MeCP2), is capable of significantly stabilizing or reversing symptoms when administered systemically into female RTT mice. To our knowledge, this is the first potential gene therapy for females afflicted with RTT.",
author = "Garg, {Saurabh K.} and Lioy, {Daniel T.} and H{\'e}l{\`e}ne Cheval and McGann, {James C.} and Bissonnette, {John M.} and Murtha, {Matthew J.} and Foust, {Kevin D.} and Kaspar, {Brian K.} and Adrian Bird and Gail Mandel",
year = "2013",
doi = "10.1523/JNEUROSCI.1854-13.2013",
language = "English (US)",
volume = "33",
pages = "13612--13620",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "34",

}

TY - JOUR

T1 - Systemic delivery of MeCP2 rescues behavioral and cellular deficits in female mouse models of Rett syndrome

AU - Garg, Saurabh K.

AU - Lioy, Daniel T.

AU - Cheval, Hélène

AU - McGann, James C.

AU - Bissonnette, John M.

AU - Murtha, Matthew J.

AU - Foust, Kevin D.

AU - Kaspar, Brian K.

AU - Bird, Adrian

AU - Mandel, Gail

PY - 2013

Y1 - 2013

N2 - De novo mutations in the X-linked gene encoding the transcription factor methyl-CPG binding protein 2 (MECP2) are the most frequent cause of the neurological disorder RETT syndrome (RTT). Hemizygous males usually die of neonatal encephalopathy. Heterozygous females survive into adulthood but exhibit severe symptoms including microcephaly, loss of purposeful hand motions and speech, and motor abnormalities, which appear after a period of apparently normal development. Most studies have focus edon male mouse models because of the shorter latency to and severity in symptoms, yet how well these mice mimic the disease in affected females is not clear. Very few therapeutic treatments have been proposed for females, the more gender-appropriate model. Here, we show that self-complementary AAV9, bearing MeCP2 CDNA under control of a fragment of its own promoter (scAAV9/MeCP2), is capable of significantly stabilizing or reversing symptoms when administered systemically into female RTT mice. To our knowledge, this is the first potential gene therapy for females afflicted with RTT.

AB - De novo mutations in the X-linked gene encoding the transcription factor methyl-CPG binding protein 2 (MECP2) are the most frequent cause of the neurological disorder RETT syndrome (RTT). Hemizygous males usually die of neonatal encephalopathy. Heterozygous females survive into adulthood but exhibit severe symptoms including microcephaly, loss of purposeful hand motions and speech, and motor abnormalities, which appear after a period of apparently normal development. Most studies have focus edon male mouse models because of the shorter latency to and severity in symptoms, yet how well these mice mimic the disease in affected females is not clear. Very few therapeutic treatments have been proposed for females, the more gender-appropriate model. Here, we show that self-complementary AAV9, bearing MeCP2 CDNA under control of a fragment of its own promoter (scAAV9/MeCP2), is capable of significantly stabilizing or reversing symptoms when administered systemically into female RTT mice. To our knowledge, this is the first potential gene therapy for females afflicted with RTT.

UR - http://www.scopus.com/inward/record.url?scp=84882718651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882718651&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1854-13.2013

DO - 10.1523/JNEUROSCI.1854-13.2013

M3 - Article

C2 - 23966684

AN - SCOPUS:84882718651

VL - 33

SP - 13612

EP - 13620

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 34

ER -